By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Coming Soon
A drug called dimenhydrinate is used to both prevent and cure motion sickness-related nausea, vomiting, and dizziness. It consists of the medicines 8-chlorotheophylline and diphenhydramine together.
Diphenhydramine is an antihistamine that prevents histamine from having its negative effects, which include the symptoms of allergies and motion sickness. A moderate stimulant that can aid in reducing drowsiness is 8-chlorotheophylline.
Both oral tablets and chewable tablets are available for dimenhydrinate. It is often taken as prescribed by a healthcare professional or 30 minutes prior to travel.
The dosage is determined by the person’s age, weight, and medical situation. Dimenhydrinate, like many medicines, can have unwanted effects include sleepiness, dry mouth, constipation, and impaired vision.
Anyone who is allergic to theophylline or diphenhydramine, or who suffers from illnesses including glaucoma, asthma, or urinary retention shouldn’t use it without first talking to a doctor. It’s crucial to carefully follow the dosage recommendations and to consult a doctor if side effects or symptoms don’t go away.
Global Dimenhydrinate Market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.
A fast-dissolving oral film has recently been created for dimenhydrinate to help with its poor solubility. A co-solvent system was used to create the oral film, modifying the solvent’s polarity to increase the water-insoluble drug’s solubility.
The dimenhydrinate oral film was created using co-solvent that contained 90% ethanol by volume. By utilising ethanol as a co-solvent, the problem of dimenhydrinate’s poor solubility was solved.
Solvent casting was used to successfully prepare the films. Acceptable results included the optimised batch’s disintegration time and the drug release.
Successful treatments for motion and seasickness include dimenhydrinate.. Galvanic stimulation of the mastoid area and the cold microcaloric test were used to examine its impact on vestibular function.
The integrity of the peripheral end organ in the labyrinth is a determining factor in the cold microcaloric test. The test was conducted using 2 cc. of ice water to examine how dimenhydrinate affected vestibular function.
